Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis

Abstract

Key-points Bone turnover makers (P1nP, B-ALP, CTX), bone modulators (Dkk1, sclerostin) and BMD were measured prospectively in rheumatoid arthritis patients treated with tofacitinib. Sclerostin increased significantly after treatment with tofacitinib, P1nP and B-ALP (markers of bone formation) decreased significantly.

Keywords

• Tofacitinib
• Bone Mineral density (BMD)
• Bone turnover markers (BTMs)
• Bone metabolism inflammation